4//SEC Filing
Rojkjaer Lisa 4
Accession 0000905148-25-000978
CIK 0001034842other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 8:56 PM ET
Size
6.0 KB
Accession
0000905148-25-000978
Insider Transaction Report
Form 4
Rojkjaer Lisa
EVP, Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
2025-03-17+9,375→ 9,375 totalExercise: $14.90Exp: 2034-03-27→ Common Stock (9,375 underlying)
Footnotes (2)
- [F1]The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.
- [F2]The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met.
Documents
Issuer
RIGEL PHARMACEUTICALS INC
CIK 0001034842
Entity typeother
Related Parties
1- filerCIK 0001846460
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 8:56 PM ET
- Size
- 6.0 KB